A PharmaShots Quarterly Analysis
Q2 was one of the most active quarters in recent memory for the pharmaceutical and biotech industry. Big Pharma leaned hard into M&A and licensing to refill pipelines, the FDA cleared a broad slate of new therapies, and AI-native partnerships continued to reshape how drugs get discovered. Below, we break down the quarter across four lenses: M&A, MedTech M&A, FDA approvals, and pharma dealmaking — with the numbers that put it all in context.
1. M&A: Big Pharma Goes Shopping — Again
Pharma M&A ran hot in Q2, with roughly 28 high-profile transactions totaling well over $107B in aggregate deal value (based on publicly disclosed figures; several deals carry undisclosed milestone components, so the real number is likely higher).
Biggest deals of the quarter:
- Sun Pharma → Organon, ~$11.75B — the largest transaction of the period, signaling continued consolidation in the generics/branded hybrid space.
- Merck KGaA → Bio-Techne, ~$11.3B
- AbbVie → Apogee Therapeutics, ~$10.9B
- GSK → Nuvalent, ~$10.6B
- CVC Capital & Groupe Bruxelles Lambert → Recordati, €10.7B (~$12.4B) — a take-private via tender offer rather than a strategic pharma acquisition, underscoring continued private-equity appetite for durable pharma cash flows.
Standout trend – Eli Lilly’s acquisition spree: Lilly was the single most acquisitive company of the quarter, closing more than six separate deals (CrossBridge Bio, Kelonia Therapeutics, Ajax Therapeutics, and a $3.8B infectious-disease pipeline build spanning three acquisitions), collectively worth north of $12.4B. This positions Lilly as the quarter’s most aggressive pipeline-builder, spanning oncology, cell therapy, and infectious disease.
Sector themes:
- Oncology and rare/orphan disease dominated target selection (Apellis, Soleno, Vega, Kartos, Catalyst).
- Neuroscience and CNS saw a notable cluster – UCB’s $1.15B move into regenerative epilepsy via Neurona, and its follow-on $2.2B acquisition of Candid Therapeutics, make UCB one of the quarter’s more active strategic consolidators alongside Lilly.
- Cell and gene therapy picked up steam (Kelonia, Tubulis-based ADC technology via Gilead’s ~$5B deal).
- European targets drew premium interest – KalVista (Chiesi, ~$1.9B), Recordati (CVC/GBL take-private), and Memo Therapeutics (Ipsen) all changed hands to non-domestic or PE acquirers, suggesting continued cross-border consolidation appetite in Europe.
2. MedTech M&A: Smaller Scale, Sharp AI/Diagnostics Focus
MedTech M&A was quieter by dollar volume but notable for its focus on diagnostics and AI-enabled tools rather than devices:
- Roche → PathAI, ~$1.05B – Roche doubling down on AI-powered pathology, reinforcing a broader industry pattern of diagnostics players acquiring AI capability rather than building it in-house.
- CareDx → Naveris, ~$260M – extends CareDx’s transplant-monitoring franchise into oncology surveillance.
- American Industrial Partners → Avanos Medical, ~$1.272B – a PE take-private of a device manufacturer.
- Novanta → Riverpoint Medical, ~$1.45B – bolt-on in surgical/med-device components.
The Roche-PathAI deal is arguably the bellwether transaction here: it reflects a maturing thesis that AI-native diagnostics companies are now attractive, de-risked M&A targets rather than early-stage bets.
3. FDA Approvals: A Broad, Diverse Quarter
The FDA cleared 14 new approvals across an unusually wide therapeutic spread – obesity, oncology, infectious disease, cardiovascular, ophthalmology, imaging, and anesthesia all saw new entrants:
| Company | Product | Indication |
| Eli Lilly | Foundayo (orforglipron) | Weight loss |
| Merck | Idvynso | Virologically suppressed HIV-1 |
| Arvinas / Pfizer | Veppanu (vepdegestrant) | ESR1-mutated breast cancer |
| BeOne Medicines | Beqalzi (sonrotoclax) | R/R mantle cell lymphoma (accelerated) |
| AstraZeneca | Baxfendy (baxdrostat) | Hard-to-control hypertension |
| Gilead | Hepcludex | Chronic hepatitis delta virus (accelerated) |
| AbbVie | Decnupaz | Blastic plasmacytoid dendritic cell neoplasm |
| Wockhardt | Zaynich | Complicated UTI, incl. pyelonephritis |
| Haisco Pharmaceutical | Cypsedo | Adult general anesthesia |
| Shionogi | Xocova | PEP COVID-19 prevention |
| Viridian Therapeutics | Lumvoa (veligrotug-vvze) | Thyroid eye disease |
| Bayer | Ambelvist (gadoquatrane) | Contrast-enhanced MRI (CNS/body lesions) |
| GSK / Spero Therapeutics | Utebzi | Complicated UTIs |
What stands out:
- Obesity remains the marquee category — Lilly’s Foundayo approval extends its GLP-1 dominance and lands amid intensifying orforglipron-class competition.
- A cUTI cluster (Zaynich, Utebzi) suggests renewed FDA and industry focus on antibacterial resistance in urinary infections — a space that had seen thin approval activity in recent years.
- Targeted oncology approvals (Veppanu, Beqalzi, Decnupaz) continue the shift toward precision, biomarker-defined indications rather than broad histology-based labels.
- Two accelerated approvals (Beqalzi, Hepcludex) highlight continued FDA reliance on the accelerated pathway for rare and hard-to-treat conditions, even amid ongoing scrutiny of that pathway.
4. Pharma Deals: Licensing and AI-Native Collaborations Explode
This was the busiest category by deal count, with more than 30 licensing, collaboration, and R&D partnerships.
Largest partnerships:
- Pfizer / Innovent Biologics, ~$10.5B – a 12-program oncology collaboration, one of the largest biotech licensing deals of the year, deepening Pfizer’s China-sourced oncology pipeline strategy.
- CytomX / Regeneron, ~$4B – expansion of a tumor-activated bispecific collaboration.
- Haisco / Eli Lilly, ~$3.05B – a broad multi-therapeutic-area license and research pact.
- Nurix Therapeutics / Roche, ~$3B – advancing bexobrutideg.
- Regeneron / Parabilis Medicines, ~$2.3B – antibody-Helicon conjugates across multiple areas.
- Profluent / Eli Lilly, ~$2.25B – AI-designed recombinases for genetic medicines.
Eli Lilly, again the standout: Beyond its acquisitions, Lilly inked separate licensing/collaboration deals this quarter (Abbisko, Ascidian, Haisco, Hanmi, Profluent, plus its earlier infectious-disease work), worth more than $12.5B in potential deal value. Combined with its M&A activity, Lilly’s total quarter-wide capital commitment across acquisitions and licensing approaches more than $25B by far the most active corporate development strategy of any company this quarter.
AI-native biotech partnerships are now mainstream, not novel:
- Alnylam / Inceptive, ~$2B – AI-powered RNAi discovery.
- Profluent / Eli Lilly, ~$2.25B – AI-designed recombinases.
- XtalPi, >$400M – GPCR-targeted small-molecule discovery partnership.
These deals mark a clear shift: AI-drug-discovery partners are no longer signing small, exploratory deals – they’re commanding billion-dollar, milestone-heavy agreements comparable to traditional biotech licensing.
5. AI Funding & AI-in-Pharma: The Infrastructure Layer Matures
Two data points capture where AI-in-pharma is heading structurally, beyond individual drug-discovery partnerships:
- Isomorphic Labs raised $2.1B in Series B funding to scale its AI drug-design engine and advance its own pipeline — one of the largest funding rounds ever for an AI-native drug discovery company, and a signal that investors are betting on platform-scale AI biotech, not just point partnerships.
- Merck partnered with Google Cloud in a ~$1B deal to build an AI-enabled enterprise platform — a move up the value chain from discovery-stage AI tools toward enterprise-wide AI infrastructure, suggesting Big Pharma is now investing as much in AI operating infrastructure as in AI-derived molecules.
The Big Picture
Putting the quarter’s disclosed figures together:
| Category | Approx. Deal Count | Approx. Total Value |
| Pharma M&A | >30 | >$110B |
| MedTech M&A | >5 | >$4B |
| Pharma Licensing/Collaboration Deals | >30 | >$60B |
| AI Funding & Infrastructure | >5 | >$4B |
| Total disclosed activity | >65 transactions | ~$167B+ |
(Figures are approximate, based on publicly disclosed upfront/total deal values in the source data. Several deals include undisclosed milestone or royalty components not captured here.)
Three takeaways for the quarter:
- Eli Lilly was the defining corporate story of Q2 – no other company came close in combined M&A and licensing volume, spanning obesity, oncology, cell therapy, infectious disease, and AI-driven genetic medicine.
- Oncology and rare disease remain the primary M&A currency, but neuroscience (UCB, Angelini) and infectious disease (Lilly, Teva) saw a meaningful resurgence.
- AI is no longer a side conversation – it showed up as a driver in drug discovery licensing (Alnylam, Profluent, XtalPi), M&A (Roche/PathAI), and enterprise infrastructure (Merck/Google Cloud), with Isomorphic Labs’ $2.1B raise underscoring investor conviction in AI-native platforms at scale.
This report is compiled from publicly announced deal terms and FDA approval disclosures for Q2. Deal values reflect disclosed upfront and/or total potential figures and may not account for all milestone or royalty terms.
